Baxter's earnings call highlighted strong growth in Medical Products & Therapies and successful recovery efforts at the North Cove facility. However, challenges such as the hurricane's impact on operations and weaknesses in certain segments like Healthcare Systems & Technologies and Pharmaceuticals were noted. Overall, the call reflects a balanced performance with both positive and negative aspects.

Company Guidance

During Baxter International's third-quarter 2024 earnings call, the company provided detailed guidance for the fourth quarter and full year 2024, despite challenges such as Hurricane Helene impacting their North Cove facility. The hurricane is expected to negatively affect total company fourth-quarter sales by approximately $200 million and adjusted earnings per share by $0.15 to $0.20. For the full year 2024, Baxter anticipates total sales growth of 1% to 2% as reported, or around 2% on a constant currency basis, and expects adjusted operating margins to increase by more than 50 basis points, despite facing a 90 to 100 basis point decline in margins from continuing operations due to stranded costs. Looking ahead to 2025, Baxter reaffirms its confidence in achieving 4% to 5% top-line growth and a 16.5% adjusted operating margin, driven by pricing strategies, supply chain improvements, and new product launches.

Strong Growth in Medical Products & Therapies

Medical Products & Therapies led all segments with 7% growth at both reported and constant currency rates, driven by positive demand across the portfolio and strong uptake of the Novum IQ platform in the U.S.

IV Solutions Production Recovery

In just 6 weeks, the North Cove team restored operations, with the highest throughput IV solutions line restarting production and a second line expected to restart soon, representing 50% of the site's total production.

Positive Earnings Per Share Performance

Total company adjusted earnings per share across continuing and discontinued operations totaled $0.80, ahead of the guidance range of $0.77 to $0.79 per share.

Infusion Hardware Growth

Infusion hardware is up 50% this year, with strong growth anticipated to continue in 2025.

---

Baxter International (BAX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BAX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jan 30, 2025	2024 (Q4)	0.52 / -	0.88	―	―	―
Nov 08, 2024	2024 (Q3)	0.78 / 0.49	0.82	-40.24% (-0.33)
Aug 06, 2024	2024 (Q2)	0.66 / 0.68	0.66	3.03% (+0.02)
May 02, 2024	2024 (Q1)	0.61 / 0.65	0.59	10.17% (+0.06)
Feb 08, 2024	2023 (Q4)	0.86 / 0.88	0.88	0.00% (0.00)
Nov 02, 2023	2023 (Q3)	0.67 / 0.82	0.82	0.00% (0.00)
Jul 27, 2023	2023 (Q2)	0.60 / 0.66	0.87	-24.14% (-0.21)
Apr 27, 2023	2023 (Q1)	0.49 / 0.59	0.93	-36.56% (-0.34)
Feb 09, 2023	2022 (Q4)	0.94 / 0.88	1.04	-15.38% (-0.16)
Oct 27, 2022	2022 (Q3)	0.81 / 0.82	1.02	-19.61% (-0.20)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

BAX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 08, 2024	$35.86	$34.46	-3.90%
Aug 06, 2024	$34.20	$36.45	+6.58%
May 02, 2024	$39.48	$36.13	-8.49%
Feb 08, 2024	$38.28	$39.32	+2.72%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---